Preoperative AminoIndex Cancer Screening (AICS) abnormalities predict postoperative recurrence in patients undergoing curative resection for non-small cell lung cancer
- PMID: 33183251
- PMCID: PMC7659101
- DOI: 10.1186/s12885-020-07575-w
Preoperative AminoIndex Cancer Screening (AICS) abnormalities predict postoperative recurrence in patients undergoing curative resection for non-small cell lung cancer
Abstract
Background: AminoIndex™ Cancer Screening (AICS (lung)) was developed as a screening test for lung cancer using a multivariate analysis of plasma-free amino acid (PFAA) profiles. According to the developed index composed of PFAA, the probability of lung cancer was categorized into AICS (lung) ranks A, B, and C in order of increasing risk. The aim of the present study was to investigate the relationship between the preoperative AICS (lung) rank and surgical outcomes in patients who underwent curative resection for non-small cell lung cancer (NSCLC).
Methods: Preoperative blood samples were collected from 297 patients who underwent curative resection for NSCLC between 2006 and 2015. PFAA concentrations were measured. The relationship between the preoperative AICS (lung) rank and clinicopathological factors was examined. The effects of the preoperative AICS (lung) rank on postoperative outcomes were also analyzed.
Results: The AICS (lung) rank was A in 93 patients (31.3%), B in 82 (27.6%), and C in 122 (41.1%). The AICS (lung) rank did not correlate with any clinicopathological factors, except for age. Based on follow-up data (median follow-up period of 6 years), postoperative recurrence was observed in 22 rank A patients (23.7%), 15 rank B (18.3%) and 49 rank C (40.2%). In the univariate analysis, preoperative AICS (lung) rank C was a worse factor of recurrence-free survival (p = 0.0002). The multivariate analysis identified preoperative AICS (lung) rank C (HR: 2.17, p = 0.0005) as a significant predictor of postoperative recurrence, particularly in patients with early-stage disease or adenocarcinoma.
Conclusion: Preoperative AICS (lung) rank C is a high-risk predictor of postoperative recurrence in patients undergoing curative resection for NSCLC.
Keywords: AICS; AICS (lung); Lung cancer; Non-small cell lung cancer; Prognosis; Recurrence; Surgery.
Conflict of interest statement
HY and SK are employees of Ajinomoto Co., Inc. (Kanagawa, Japan). MH and TA have received research grants from Ajinomoto Co., Inc. (Kanagawa, Japan). This does not alter the authors’ adherence to journal’s policies. The remaining authors declare that they have no competing interests.
Figures



Similar articles
-
Post-operative AICS status in completely resected lung cancer patients with pre-operative AICS abnormalities: predictive significance of disease recurrence.Sci Rep. 2018 Aug 17;8(1):12378. doi: 10.1038/s41598-018-30685-2. Sci Rep. 2018. PMID: 30120365 Free PMC article.
-
Perioperative dynamics and significance of plasma-free amino acid profiles in colorectal cancer.BMC Surg. 2018 Feb 21;18(1):11. doi: 10.1186/s12893-018-0344-0. BMC Surg. 2018. PMID: 29466971 Free PMC article.
-
Hazards of Recurrence, Second Primary, or Other Tumor at Ten Years After Surgery for Non-Small-Cell Lung Cancer.Clin Lung Cancer. 2020 Jul;21(4):333-340. doi: 10.1016/j.cllc.2020.02.011. Epub 2020 Feb 26. Clin Lung Cancer. 2020. PMID: 32273257
-
Does blood transfusion increase the chance of recurrence in patients undergoing surgery for lung cancer?Interact Cardiovasc Thorac Surg. 2012 Jan;14(1):85-90. doi: 10.1093/icvts/ivr025. Epub 2011 Nov 15. Interact Cardiovasc Thorac Surg. 2012. PMID: 22108935 Free PMC article. Review.
-
Local recurrence following lung cancer surgery: incidence, risk factors, and outcomes.Surg Oncol. 2013 Sep;22(3):156-61. doi: 10.1016/j.suronc.2013.04.002. Epub 2013 May 20. Surg Oncol. 2013. PMID: 23702313 Free PMC article. Review.
Cited by
-
Adjuvant immunotherapy improves survival in completely resected stage IB-III NSCLC: a systematic review and meta-analysis.Front Oncol. 2025 Apr 8;15:1493221. doi: 10.3389/fonc.2025.1493221. eCollection 2025. Front Oncol. 2025. PMID: 40265009 Free PMC article.
-
Evaluation of an innovative multi-cancer early detection test: high sensitivity and specificity in differentiating cancer, inflammatory conditions, and healthy individuals.Front Oncol. 2025 Mar 6;15:1520869. doi: 10.3389/fonc.2025.1520869. eCollection 2025. Front Oncol. 2025. PMID: 40115017 Free PMC article.
-
Changes in serum amino acid levels in non-small cell lung cancer: a case-control study in Chinese population.PeerJ. 2022 Apr 20;10:e13272. doi: 10.7717/peerj.13272. eCollection 2022. PeerJ. 2022. PMID: 35469201 Free PMC article.
References
-
- Okamoto N. Use of “AminoIndex Technology” for cancer screening. Ningen Dock. 2012;26(6):911–922.
-
- Hiller K, Metallo CM. Profiling metabolic networks to study cancer metabolism. Curr Opin Biotechnol. 2013;24(1):60–68. - PubMed
-
- Mazzone PJ, Wang XF, Beukemann M, Zhang Q, Seeley M, Mohney R, Holt T, Pappan KL. Metabolite Profiles of the Serum of Patients with Non-Small Cell Carcinoma. J Thorac Oncol. 2016;11(1):72–78. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical